Obesity – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Obesity – Pipeline Review, H2 2019’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Obesity

– The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects

– The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Obesity

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aardvark Therapeutics Inc

Adocia SAS

AgeX Therapeutics Inc

Akero Therapeutics Inc

Alla Chem LLC

Altimmune Inc

Amgen Inc

Antag Therapeutics ApS

Aoxing Pharmaceutical Company Inc

Applied Molecular Transport LLC

AptamiR Therapeutics Inc

Aptorum Group Ltd

Armata Pharmaceuticals Inc

AstraZeneca Plc

Athersys Inc

Auris Medical Holding Ltd

Betagenon AB

BioRestorative Therapies Inc

Biozeus Pharmaceutical SA

Boehringer Ingelheim International GmbH

Braasch Biotech LLC

Bukwang Pharm Co Ltd

Caliway Biopharmaceutics Co Ltd

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Carmot Therapeutics Inc

Cellivery Therapeutics Inc

Celon Pharma SA

Centeer BioTherapeutics Ltd Co

Chong Kun Dang Pharmaceutical Corp

CohBar Inc

CoMentis Inc

Corbus Pharmaceuticals Inc

Corcept Therapeutics Inc

Curacle Co Ltd

D&D Pharmatech Co Ltd

DD Therapeutics LLC

Diasome Pharmaceuticals Inc

DiscoveryBiomed Inc

Eli Lilly and Co

Ember Therapeutics Inc (Inactive)

Empros Pharma AB

EncuraGen Inc

EraCal Therapeutics AG

Eternygen GmbH

Evecxia Inc

FGH BioTech Inc

Gila Therapeutics Inc

Gilead Sciences Inc

Glaceum Inc

Glucox Biotech AB

Gmax Biopharm Ltd

Gubra ApS

HanAll Biopharma Co Ltd

Hangzhou Adamerck Pharmlabs Inc

Hanmi Pharmaceuticals Co Ltd

Helsinn Group

Immune Biosolutions Inc

Immungenetics AG

Infusion Biosciences

Innovimmune Biotherapeutics Inc

Intarcia Therapeutics Inc

Japan Tobacco Inc

Jenrin Discovery Inc

Johnson & Johnson

Juno Therapeutics Inc

KinDex Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

KoBioLabs Inc

Lead Discovery Center GmbH

LG Chem Ltd

Liaoning Kanion Warwick Pharmaceutical Co Ltd

Liminal BioSciences Inc

Lipidio Pharmaceuticals Inc

Living Cell Technologies Ltd

Lixte Biotechnology Holdings Inc

LNC Therapeutics SA

Lobesity LLC

Lynkogen Inc

MAKScientific LLC

Merck & Co Inc

Mirabilis Therapeutics BV

Nano Intelligent Biomedical Engineering Corp

NeuroNano Pharma Inc

NGM Biopharmaceuticals Inc

Nordic Bioscience AS

Novartis AG

NovMetaPharma Co Ltd

Novo Nordisk AS

Nubiyota LLC

NuSirt Biopharma Inc

ObeTherapy Biotechnology

Omeros Corp

OPKO Health Inc

Oramed Pharmaceuticals Inc

Orbis Biosciences Inc

Palatin Technologies Inc

PegBio Co Ltd

Pfizer Inc

PharmaIN Corp

Poxel SA

Preveceutical Medical Inc

Raziel Therapeutics

Regeneron Pharmaceuticals Inc

Renova Therapeutics Inc

Reviva Pharmaceuticals Inc

Rhamnopharma Inc

Rhythm Pharmaceuticals Inc

Saniona AB

Sanofi

Scioto Biosciences Inc

Scohia Pharma Inc

Seres Therapeutics Inc

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shionogi & Co Ltd

Sigrid Therapeutics AB

Siragen Pharmaceuticals Inc

SJT Molecular Research SL

Symmetry Therapeutics Inc

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Talapo Therapeutics Inc

Techfields Pharma Co Ltd

Toray Industries Inc

Ube Industries Ltd

Virtici LLC

Vivus Inc

WhanIn Pharmaceutical Co Ltd

XL-protein GmbH

Yuhan Corp

Yuyu Pharma Inc

Zafgen Inc

Zealand Pharma AS

Zhejiang Doer Biologics Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Obesity Overview 9

Obesity Therapeutics Development 10

Obesity Therapeutics Assessment 38

Obesity Companies Involved in Therapeutics Development 56

Obesity Drug Profiles 98

Obesity Dormant Projects 465

Obesity Discontinued Products 485

Obesity Product Development Milestones 489

Appendix 499

List of Tables

List of Tables

Number of Products under Development for Obesity, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Obesity – Pipeline by Aardvark Therapeutics Inc, H2 2019

Obesity – Pipeline by Adocia SAS, H2 2019

Obesity – Pipeline by AgeX Therapeutics Inc, H2 2019

Obesity – Pipeline by Akero Therapeutics Inc, H2 2019

Obesity – Pipeline by Alla Chem LLC, H2 2019

Obesity – Pipeline by Altimmune Inc, H2 2019

Obesity – Dormant Projects, H2 2019

Obesity – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Obesity, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports